Erratum: The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation [EMBO Mol Med, 5, (2013) 1523-1536, DOI: 10.1002/emmm.201302847];The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

EMBO Molecular Medicine

Volumn 5, Issue 10, 2013, Pages 1523-1536

  Lucá, Rossella ^a,b   Averna, Michele ^a,b   Zalfa, Francesca ^c,d   Vecchi, Manuela ^e,f   Bianchi, Fabrizio ^f   Fata, Giorgio La ^a,b   Del Nonno, Franca ^g   Nardacci, Roberta ^g   Bianchi, Marco ^e   Nuciforo, Paolo ^h   Munck, Sebastian ^a,b   Parrella, Paola ⁱ   Moura, Rute ^a,b   Signori, Emanuela ^j   Alston, Robert ^k   Kuchnio, Anna ^a,b   Farace, Maria Giulia ^d   Fazio, Vito Michele ^c,i   Piacentini, Mauro ^d,g   De Strooper, Bart ^a,b   Achsel, Tilmann ^a,b   Neri, Giovanni ^l   Neven, Patrick ^m   Evans, D Gareth ^k,n   Carmeliet, Peter ^a,b   Mazzone, Massimiliano ^a,b   Bagni, Claudia ^a,b,e   more..

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l CATHOLIC UNIVERSITY   (Italy)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ ST MARY S HOSPITAL   (United Kingdom)

more..

Author keywords

Cell invasion; EMT; FMRP; MRNA metabolism; TNBC

Indexed keywords

CAVEOLIN 2; CYTOKERATIN 14; DESMOPLAKIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; FIBRONECTIN; FRAGILE X MENTAL RETARDATION PROTEIN; GELATINASE B; JAGGED1; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICROTUBULE ASSOCIATED PROTEIN 5; NOTCH1 RECEPTOR; OCCLUDIN; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL ADHESION; CELL INVASION; CELL SHAPE; CELL SPREADING; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROBABILITY; PROTEIN RNA BINDING; RNA STABILITY; TRIPLE NEGATIVE BREAST CANCER;

CELL INVASION; EMT; FMRP; MRNA METABOLISM; TNBC;

ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SHAPE; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; VIMENTIN;

EID: 84884926024     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201470030     Document Type: Erratum

References (77)

1. Ascano M, Jr., Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, Langlois C, Munschauer M, Dewell S, Hafner M, et al (2012) FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492: 382-386
2. Bagni C, Greenough WT (2005) From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 6: 376-387
3. Bagni C, Tassone F, Neri G, Hagerman R (2012) Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 122: 4314-4322
4. Bassell GJ, Warren ST (2008) Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214
5. Berx G, van Roy F (2009) Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129
6. Bhakar AL, Dolen G, Bear MF (2012) The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35: 417-443
7. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46: 94-102
8. Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, et al (2009) Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat 115: 349-358
9. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107: 477-487
10. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70
11. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83
12. Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, Boldorini R, Pallotti F, Viale G, Gishizky ML, et al (2006) Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res 66: 8147-8154
13. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331: 1559-1564
14. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST (2009) Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 85: 503-514
15. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9: 730-756
16. Confalonieri S, Quarto M, Goisis G, Nuciforo P, Donzelli M, Jodice G, Pelosi G, Viale G, Pece S, Di Fiore PP (2009) Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene 28: 2959-2968
17. Cowin P, Rowlands TM, Hatsell SJ (2005) Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17: 499-508
18. D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, Kooy RF (2006) Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 1121: 238-245
19. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, et al (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146: 247-261
20. De Rubeis S, Bagni C (2010) Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability. Mol Cell Neurosci 43: 43-50
21. Del Duca D, Werbowetski T, Del Maestro RF (2004) Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 67: 295-303
22. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214
23. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19: 403-410
24. Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C (2007) The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34: 343-354
25. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
26. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827
27. Graff JR, Zimmer SG (2003) Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20: 265-273
28. Gross C, Berry-Kravis EM, Bassell GJ (2012) Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37: 178-195
29. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674
30. Hattermann K, Held-Feindt J, Mentlein R (2011) Spheroid confrontation assay: A simple method to monitor the three-dimensional migration of different cell types in vitro. Ann Anat 193: 181-184
31. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485: 55-61
32. Huber GF, Zullig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ (2011) Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 11: 211-218
33. Hudis CA, Gianni L (2011) Triple-negative breast cancer: An unmet medical need. Oncologist 16: 1-11
34. Jeong H, Ryu YJ, An J, Lee Y, Kim A (2012) Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60: E87-E95
35. Kalkunte R, Macarthur D, Morton R (2007) Glioblastoma in a boy with fragile X: An unusual case of neuroprotection. Arch Dis Child 92: 795-796
36. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13: R59
37. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428
38. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118: 277-279
39. Kim SA, Tai CY, Mok LP, Mosser EA, Schuman EM (2011) Calcium-dependent dynamics of cadherin interactions at cell-cell junctions. Proc Natl Acad Sci USA 108: 9857-9862
40. Kim TY, Vigil D, Der CJ, Juliano RL (2009) Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 28: 77-83
41. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W, Buerger H (2005) The origin of vimentin expression in invasive breast cancer: Epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206: 451-457
42. Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres K, Langley RR, Lazar AJ, Hung MC, et al (2010) Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5: e10105
43. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, Xue Q (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129: 43-51
44. Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, Guan X, Zhang J, Feng Z (2007) Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 18: 943-951
45. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104: 6740-6745
46. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J (2003) RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37: 417-431
47. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G (1983) TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1: 373-380
48. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, et al (2008) The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134: 1042-1054
49. Nasr Z, Pelletier J (2012) Tumor progression and metastasis: Role of translational deregulation. Anticancer Res 32: 3077-3084
50. Nieto MA (2011) The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 347-376
51. Nieto MA, Cano A (2012) The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin Cancer Biol 22: 361-368
52. Olson MF, Sahai E (2009) The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26: 273-287
53. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46: 685-693
54. Reddy KB (2011) Triple-negative breast cancers: An updated review on treatment options. Curr Oncol 18: e173-179
55. Rosales-Reynoso MA, Ochoa-Hernandez AB, Aguilar-Lemarroy A, Jave-Suarez LF, Troyo-Sanroman R, Barros-Nunez P (2010) Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. Arch Med Res 41: 110-118 e112
56. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7: 737-749
57. Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68: 3033-3046
58. Schmalhofer O, Brabletz S, Brabletz T (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166
59. Schmid RS, Maness PF (2008) L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth. Curr Opin Neurobiol 18: 245-250
60. Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U (2001) Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet 103: 226-230
61. Schuster R, Max N, Mann B, Heufelder K, Thilo F, Grone J, Rokos F, Buhr HJ, Thiel E, Keilholz U (2004) Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 108: 219-227
62. Silva JM, Ezhkova E, Silva J, Heart S, Castillo M, Campos Y, Castro V, Bonilla F, Cordon-Cardo C, Muthuswamy SK, et al (2009) Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell 137: 1047-1061
63. Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10: 254-266
64. Stumpf CR, Ruggero D (2011) The cancerous translation apparatus. Curr Opin Genet Dev 21: 474-483
65. Tao K, Fang M, Alroy J, Sahagian GG (2008) Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 8: 228
66. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890
67. Turk J (2011) Fragile X syndrome: Lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry 24: 387-397
68. Van Belle V, Van Calster B, Wildiers H, Van Huffel S, Neven P (2009) Lymph node ratio better predicts disease-free survival in node-positive breast cancer than the number of positive lymph nodes. J Clin Oncol 27: e150-151 author reply e152
69. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
70. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679
71. Wilby MJ, Muir EM, Fok-Seang J, Gour BJ, Blaschuk OW, Fawcett JW (1999) N-Cadherin inhibits Schwann cell migration on astrocytes. Mol Cell Neurosci 14: 66-84
72. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11: 8006-8014
73. Wyckoff J, Gligorijevic B, Entenberg D, Segall J, Condeelis J (2011) High-resolution multiphoton imaging of tumors in vivo. Cold Spring Harb Protoc 2011: 1167-1184
74. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33
75. Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, Kim IS, Hong JT, Sung JH, Son BC, et al (2012) E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol
76. Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, di Penta A, Tabolacci E, Chiurazzi P, Neri G, Grant SG, et al (2007) A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 10: 578-587
77. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C (2003) The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112: 317-327